Literature DB >> 3710430

The hemodynamic effect of verapamil on portal hypertension in patients with postnecrotic cirrhosis.

C W Kong, C S Lay, Y T Tsai, C L Yeh, K H Lai, S D Lee, K J Lo, B N Chiang.   

Abstract

Wedged hepatic venous pressure, free hepatic venous pressure and cardiac index were measured before and 1 hr after i.v. administration as well as 1 month and 3 months after chronic oral administration of verapamil in 10 patients with HBsAg-positive cirrhosis. The gradient between wedged hepatic venous pressure and free hepatic venous pressure was decreased 14% at 1 hr after i.v. administration of 10 mg verapamil, and the sustained decrease in hepatic venous pressure gradient was also demonstrated in the patients after 1 month, and in six patients after 3 months of continuous oral administration of verapamil. The mean arterial pressure significantly decreased (p less than 0.01) 1 hr after the administration of verapamil. There was no significant change in other hemodynamic values. We conclude that chronic oral administration of verapamil can reduce the hepatic venous pressure gradient in patients with compensated HBsAg-positive cirrhosis and portal hypertension.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3710430     DOI: 10.1002/hep.1840060317

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Effects of calcium antagonists on hepatic and systemic hemodynamics in awake portal hypertensive rats.

Authors:  M Nagasawa; T Kawasaki; T Yoshimi
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

Review 2.  The use of sclerotherapy for the management of oesophageal varices in portal hypertension.

Authors:  J Terblanche
Journal:  Surg Endosc       Date:  1988       Impact factor: 4.584

3.  Effect of verapamil on nitric oxide synthase in a portal vein-ligated rat model: role of prostaglandin.

Authors:  Chii-Shyan Lay; C-M-Y May; Fa-Yauh Lee; Yang-Te Tsai; Shou-Dong Lee; Shu Chien; Shlomoh Sinchon
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

Review 4.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

5.  Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis.

Authors:  C Merkel; M Bolognesi; P Angeli; G F Finucci; P Amodio; S Bellon; A Gatta
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

6.  The calcium-channel blocker, verapamil, does not improve portal pressure in patients with alcoholic cirrhosis.

Authors:  C Merkel; A Gatta; M Bolognesi; R Padrini; G F Finucci; P Angeli; A Ruol
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

7.  Prophylaxis of first variceal hemorrhage in patients with liver cirrhosis.

Authors:  T Sauerbruch; G Kleber; A Gerbes; G Paumgartner
Journal:  Klin Wochenschr       Date:  1986-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.